专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023084000A1 4H-IMIDAZO[1,5-B]PYRAZOLE DERIVATIVES FOR DIAGNOSIS 审中-公开
公开(公告)号：WO2023084000A1
公开(公告)日：2023-05-19
申请号：PCT/EP2022/081555
申请日：2022-11-10
申请人： AC IMMUNE SA
发明人： MOLETTE, Jérôme
IPC分类号： C07D487/04 , A61K31/4162 , A61K51/00
摘要： The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites (such as Parkinson's disease), determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.

2. 发明申请

WO2023073075A1 BIOMARKER FOR IMMUNE CHECKPOINT INHIBITOR SENSITIVE CANCER 审中-公开
公开(公告)号：WO2023073075A1
公开(公告)日：2023-05-04
申请号：PCT/EP2022/080026
申请日：2022-10-26
申请人： SCAILYTE AG , GENINUS INC.
发明人： DONATO, Cinzia , ESSIGMAN, Benjamin , PARK, Woong-yang , KIM, Nayoung
IPC分类号： C12Q1/6886
摘要： The invention relates to methods for diagnosing, predicting disease development, disease progression and/or disease outcome, predicting susceptibility to treatment and/or classification in the context of immune checkpoint inhibitor treatable cancer, wherein a combination of biomarkers from Table 1 is determined. The invention further relates to pharmaceutical products for use in patients stratified according to the methods of the invention and to compositions comprising reagents for the detection of the combination of biomarkers from Table 1 for the diagnosis of immune checkpoint inhibitor treatable cancer.

3. 发明申请

WO2023062147A1 MONITORING SUBSTATIONS OF A POWER GRID 审中-公开
公开(公告)号：WO2023062147A1
公开(公告)日：2023-04-20
申请号：PCT/EP2022/078554
申请日：2022-10-13
申请人： HITACHI ENERGY SWITZERLAND AG
发明人： MERKERT, Lennart
IPC分类号： H02B1/56 , G01M3/00 , H02J13/00 , G01M3/04 , G01M3/18
摘要： The present disclosure relates to a method for monitoring a plurality of heaters and/or determining water ingress in at least one substation. The method comprises receiving, by a controller from a first sensor a first at least one environmental condition of a first section of the at least one substation; receiving, by the controller from a second sensor a second at least one environmental condition of a second section of the at least one substation; and providing a warning signal, by the controller, according to a difference between the first at least one environmental condition and the second at least one environmental condition. The present disclosure also relates to a respective controller and system.

4. 发明申请

WO2023046707A1 SYSTEM FOR IN-FLIGHT DETECTION OF PHYSIOLOGICAL DATA AND KIT FOR IN-FLIGHT MONITORING OF PHYSIOLOGICAL PARAMETERS 审中-公开
公开(公告)号：WO2023046707A1
公开(公告)日：2023-03-30
申请号：PCT/EP2022/076146
申请日：2022-09-21
申请人： AIRCRAFT CABIN MODIFICATION GMBH
发明人： NOSHARI, Arash , THAHER, Rami , OEHLER, Martin
IPC分类号： B64D11/00 , B60N2/00
摘要： The invention relates to a system (10) for detecting physiological data of a person in-flight in an aircraft, including at least one aircraft seat (12) and/or at least one aircraft bed (112) and at least one detecting device (26) including at least one capacitive sensor (28) integrated in the aircraft seat (12) and/or the aircraft bed (112), respectively. The capacitive sensor (28) is configured to sense at least one physiological value of a person, when the person is arranged on at least a portion of the aircraft seat (12) or aircraft bed (112). The capacitive sensor (28) is further configured to generate at least one physiological signal based on the sensed physiological value. The invention also relates to a kit for in-flight monitoring of at least one physiological parameter of a person in-flight in an aircraft, including a system as described herein and an evaluating device.

5. 发明申请

WO2023021190A1 NOVEL CATHEPSIN INHIBITORS 审中-公开
公开(公告)号：WO2023021190A1
公开(公告)日：2023-02-23
申请号：PCT/EP2022/073211
申请日：2022-08-19
申请人： ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
发明人： ORICCHIO, Elisa , PETRUZZELLA, Aaron , CORREIA, Bruno
IPC分类号： C07K7/06 , A61K38/00 , C07K14/81 , C12N9/50
摘要： The present invention relates to a cathepsin inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) wherein (X1) is an amino acid selected from K, L, F and M; (X2) is an amino acid selected from L, A, D, E, F, G, H, I, K, M, N, S, W, Y, Q and R; (X3) is an amino acid selected from R, A and L; (X4) is an amino acid selected from M, I, K, V and Y; (X5) is an amino acid selected from P, A, I, L, V, W and Y; (X6) is an amino acid selected from K, A, E, F, G, I, L, M, N, Q, S, T, V, W, Y and Q; (X7) is an amino acid selected from D, A, E, F, G, I, L, M, N, P, T, V, W, Y, Q and R; and (Y) is a Michael acceptor.

6. 发明申请

WO2023020688A1 METHOD FOR CDNA LIBRARY CONSTRUCTION AND ANALYSIS FROM TRANSFER RNA 审中-公开
公开(公告)号：WO2023020688A1
公开(公告)日：2023-02-23
申请号：PCT/EP2021/072902
申请日：2021-08-18
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
发明人： NEDIALKOVA, Danny D. , BEHRENS, Andrew , RODSCHINKA, Geraldine
IPC分类号： C12N15/10
摘要： The present invention relates to a method for the generation of a cDNA library from transfer RNA (tRNA) comprising (a) optionally ligating at least one DNA adapter to the 3'-end oftRNA, wherein the 3'-end of the DNA adapter is preferably a chain terminator dideoxycytidine, preferably under one or more of the following conditions: (i) crowding reagent at 5% to 35%, preferably 15% to 30%, and most preferably about 25%, (ii) MgCI2 concentration of 1 mM to 15 mM, preferably 3 to 12 mM and most preferably about 10 mM (iii) a temperature of 12°C to 37°C, preferably of about 25°C. (iv) a pH of 6.0 to 9.0, preferably 6.5 to 8.0 and most preferably about 7.0, (v) reducing agent concentration of 0.1 mM to 10 mM, preferably 0.5 to 5 mM and most preferably about 1 mM, and (vi) a reaction time of at least 30 min, preferably at least 1.5 h and most preferably at least 3 h; and (b) reverse transcription in a primer- dependent reaction, in case step (a) is present, or in a template-switching reaction, in case step (a) is absent, of tRNAs into cDNA by a group II intron reverse transcriptase, under the following conditions: (i) KCI or NaCI at a concentration of 20 mM to 250 mM, preferably 50 to 100 mM and most preferably about 75 mM, (ii) MgCh at a concentration of 0.5 mM to 15 mM, preferably 1 to 5 mM and most preferably about 3 mM, (iii) a temperature of 30°C to 65°C, preferably of about 42°C, and (iv) a reaction time of at least 2 h, preferably at least 8 h and most preferably at least 15 h, and preferably (v) a pH of 6.5 to 9.5, preferably 7.0 to 8.5 and most preferably about 8.0, and/or (vi) a reducing agent (DTT) at a concentration of 1 mM to 12.5 mM, preferably 3 to 8 mM and most preferably about 5 mM.

7. 发明申请

WO2023016826A2 METHOD AND MEANS FOR ENHANCING THERAPEUTIC ANTIBODIES 审中-公开
公开(公告)号：WO2023016826A2
公开(公告)日：2023-02-16
申请号：PCT/EP2022/071294
申请日：2022-07-28
申请人： VACCINVENT GMBH , UNIVERSITÄT ULM
发明人： JUMAA-WEINACHT, Hassan
IPC分类号： A61K39/12 , C07K16/28 , C07K16/26 , C07K16/44 , A61K39/00
摘要： The invention relates to a pharmaceutical composition comprising an IgM antibody or a fragment thereof and a therapeutic antibody, wherein the IgM antibody specifically binds to the therapeutic antibody. The invention further relates to a method of treatment of a disease or disorder, the method comprising the steps of: a) administering an effective dose of a therapeutic antibody; and b) administering a corresponding dose of an IgM antibody or a fragment thereof, wherein the IgM antibody specifically binds to the therapeutic antibody.

8. 发明申请

WO2023001905A1 NOVEL ANTIFUNGAL COMPOUNDS 审中-公开
公开(公告)号：WO2023001905A1
公开(公告)日：2023-01-26
申请号：PCT/EP2022/070389
申请日：2022-07-20
申请人： SELMOD GMBH
发明人： KNECHTLE, Philipp , GOMBERT, Frank Otto , RIEDL, Rainer , LINDENMANN, Urs , KREBS, Walter , WIPFLI, Dennis , ALBERT, Ina , WEGMANN, Sandro , SCHMID, Andrina
IPC分类号： A61P31/10 , C07C57/00 , C07C57/18 , C07C57/52 , C07C59/58 , C07C59/60 , C07C311/51 , C07D307/54 , C07F9/113
摘要： The present invention refers to a compound having the formula (I): R1–Z–C≡C–C≡C–R3 (I) and pharmaceutical compositions comprising the same that can be used in prevention, treatment and alleviation of a fungal infection. The instant compounds and pharmaceutical compositions are particularly useful in treating, preventing and alleviating fungal infections caused by Candida fungi and Aspergillus fungi.

9. 发明申请

WO2023275274A1 METHODS AND DEVICES FOR RATIOMETRIC CHARACTERIZATION OF FLUORESCENT PARTICLES 审中-公开
公开(公告)号：WO2023275274A1
公开(公告)日：2023-01-05
申请号：PCT/EP2022/068114
申请日：2022-06-30
申请人： NANOTEMPER TECHNOLOGIES GMBH
发明人： BAASKE, Philipp , LANGER, Patrick Andreas Markus
IPC分类号： G01N15/06 , G01N33/533 , G01N33/58 , G01N21/64 , G01N2021/6419 , G01N2021/6421 , G01N33/582
摘要： The present invention relates to devices and methods for the characterization of fluorescently labeled particles in solution by analyzing alterations in the fluorescence spectrum of the fluorescently labeled particles. In particular, a sample of fluorescently labeled particles is analyzed under different conditions/ environments by fluorescent excitation and detection of the corresponding fluorescence emissions. The particles are characterized by analyzing the detected fluorescence emissions under these different conditions/ environments. More specifically, the present invention relates to methods and devices for ratiometric characterization of inter- and/or intramolecular interactions, and/or conformational modifications and/or localization of fluorescently labeled particles.

10. 发明申请

WO2023275213A1 CLOTTABILITY-BASED PERSONALIZED TREATMENT (CPT) SYSTEM 审中-公开
公开(公告)号：WO2023275213A1
公开(公告)日：2023-01-05
申请号：PCT/EP2022/068005
申请日：2022-06-29
申请人： PUN, San
发明人： PUN, San
IPC分类号： G01N33/86 , G01N33/68 , G01N33/6893
摘要： The present invention provides a method for modelling clottability of a blood sample, comprising determining clottability of blood samples or providing blood samples with known clottability due to the direct effects of biological activities of immune and blood coagulation systems on clottability; determining and attributing a health status and risk factor for thrombosis and/or bleeding to the donor having provided the respective sample; determining the pharmacodynamic effect(s) of one or more drug(s) including anti-inflammatory, anticoagulant(s) and the corresponding therapeutic range(s) on the blood sample to reduce inflammation and/or the risk(s) of thrombosis and/or bleeding; and modelling the clottability of a blood sample after administering the most effective therapeutic strategy involving drugs including anticoagulant to said blood sample.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式